ABVX · Abivax SA
Is ABVX setting up for a breakout, what are traders on X and the news saying, are its insiders buying, and how is the business doing? Everything Raspberry Trades measures on Abivax SA, in one place.
Today's breakout radarIs ABVX setting up for a breakout?
Breakout Radar API →Not today. ABVX is not on today's radar: no tight base just under a resistance that has been tested again and again.
See the stocks that are setting up today →What are traders on X saying about ABVX?
Stock Sentiment API →Bulls: Obefazimod is described as a best-in-class oral drug that essentially "cures" UC, with multiple recent data updates and clarity affirming it, and Crohn's data highly anticipated; bulls argue the company holds strong bargaining power in buyout talks and is negotiating for a higher price, with deal speculation still alive. ABVX clocked its best day in 11 months on analyst upgrades after fresh data eased drug safety concerns.
Bears: Bears flag a mega gap down on a safety scare and warn the stock "should come with a black box warning." They argue funds see upside capped with data out and Crohn's not until mid-2027, making ABVX an easy funding source, and that the longer a deal takes the lower it falls, with one call for $60 and another cheerleading a drop to $30 in 6-12 months. Volume hit a new low of 432k Friday, and the stock was noted trading below trend.
Reading from Oct 27, 2026; each post classified by AI, weighted by engagement.
What is the news saying about ABVX?
News Sentiment API →No recent news reading for ABVX. The News Sentiment API reads today's headlines on any US stock.
Are ABVX insiders buying or selling?
Insider Trading API →Open-market trades only, from SEC Form 4 filings — option exercises, tax withholding and grants are left out.
Every ABVX insider trade →What does Abivax SA expect?
Company Guidance API →- Q4 2027 · cash runway · 6-K filed May 22, 2026
“providing a projected cash runway into Q4 2027 based on current operating assumptions”
- late Q2 2026 · topline results of uc abtect phase 3 maintenance trial · 6-K filed May 22, 2026
“Topline results of UC ABTECT Phase 3 maintenance trial - late Q2 2026”
- September 21, 2026 · half-year financial results · 6-K filed May 22, 2026
“Half-Year Financial Results - September 21, 2026”
- Q4 2026 · topline results of phase 2b induction trial for cd · 6-K filed May 22, 2026
“Topline results of Phase 2b induction trial for CD - Q4 2026”
Quoted from the outlook the company filed with the SEC.
Free account, no card: today's top 5 with charts, by email before the open.
Measured data, not recommendations. Not investment advice.